XLO trades 987.7% below Wall Street's consensus target of $98.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes XLO achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 3, 2026, Xilio Therapeutics, Inc. (XLO) has a Wall Street consensus price target of $98.00, based on estimates from 3 covering analysts. With the stock currently trading at $9.01, this represents a potential upside of +987.7%. The company has a market capitalization of $175M.
Analyst price targets range from a low of $98.00 to a high of $98.00, representing a 0% spread in expectations. The median target of $98.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, XLO trades at a trailing P/E of -2.2x. Analysts expect EPS to grow -130.2% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 NKTXNkarta, Inc. | $184M | $2.58 | $9.00 | +249.5% | Buy | — | 12 |
 IMVTImmunovant, Inc. | $6.9B | $33.62 | $40.00 | +19.0% | Buy | — | 23 |
 RCUSArcus Biosciences, Inc. | $3.1B | $24.44 | $40.00 | +63.7% | Buy | — | 18 |
 AGENAgenus Inc. | $348M | $8.36 | $25.00 | +199.0% | Buy | 31.3x | 11 |
 CLDXCelldex Therapeutics, Inc. | $2.1B | $31.65 | $66.80 | +111.1% | Buy | — | 20 |
 TGTXTG Therapeutics, Inc. | $8.3B | $54.29 | $80.50 | +48.3% | Buy | 55.8x | 13 |
 NUVLNuvalent, Inc. | $9.1B | $123.96 | $127.32 | +2.7% | Hold | — | 19 |
 ALKSAlkermes plc | $7.0B | $41.75 | $58.83 | +40.9% | Buy | — | 29 |
 KYMRKymera Therapeutics, Inc. | $8.8B | $107.39 | $138.07 | +28.6% | Buy | — | 27 |
 REGNRegeneron Pharmaceuticals, Inc. | $75.7B | $735.20 | $844.26 | +14.8% | Buy | 13.5x | 49 |
Quick answers to the most common questions about buying XLO stock.
The consensus Wall Street price target for XLO is $98, representing 987.7% upside from the current price of $9.01. With 3 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
XLO has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $98 implies 987.7% upside from current levels.
XLO's current price is $9.01 with a consensus target of $98 (987.7% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $98 for XLO, while the most conservative target is $98. The consensus of $98 represents the median expectation. These targets typically reflect 12-month expectations.
XLO is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month XLO stock forecast based on 3 Wall Street analysts shows a consensus price target of $98, with estimates ranging from $98 (bear case) to $98 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on XLO, with a "Buy" consensus rating and $98 price target (987.7% upside). 3 of 3 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
XLO analyst price targets range from $98 to $98, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $98 consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.